Article
Oncology
Patrick A. Ott, Matthew Nazzaro, Kathleen L. Pfaff, Evisa Gjini, Kristen D. Felt, Jacquelyn O. Wolff, Elizabeth Buchbinder, Rizwan Haq, Ryan J. Sullivan, Donald P. Lawrence, David F. McDermott, Mariano Severgnini, Anita Giobbie-Hurder, Scott J. Rodig, F. Stephen Hodi
Summary: The combination therapy of Tremelimumab and MEDI3617 was found to be safe in patients with advanced melanoma, but no significant immune-related complete or partial responses were observed. Inhibition of angiopoietin-2 combined with immune checkpoint inhibition deserves further exploration.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Anna M. W. ten Voorde, Annemijn P. A. Wierenga, Rogier J. Nell, Pieter A. van der Velden, Gregorius P. M. Luyten, Robert M. Verdijk, Martine J. Jager
Summary: In uveal melanoma, ANG-2 is identified as an important prognostic factor, with high expression associated with high-risk tumors and metastasis development, making it a potential therapeutic target.
Review
Urology & Nephrology
Mei Li, Zoran Popovic, Chang Chu, Christoph Reichetzeder, Wolfgang Pommer, Bernhard K. Kramer, Berthold Hocher
Summary: Background: Angiopoietins (Ang) are essential angiogenic factors involved in angiogenesis, vascular maturation, and inflammation. The most studied angiopoietins, angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2), behave antagonistically to each other in vivo to sustain vascular endothelium homeostasis. While Ang-1 typically acts as the endothelium-protective mediator, its context-dependent antagonist Ang-2 can promote endothelium permeability and vascular destabilization, hence contributing to a poor outcome in vascular diseases via endothelial injury, vascular dysfunction, and microinflammation. The pathogenesis of kidney diseases is associated with endothelial dysfunction and chronic inflammation in renal diseases. Summary: Several preclinical studies report overexpression of Ang-2 in renal tissues of certain kidney disease models; additionally, clinical studies show increased levels of circulating Ang-2 in the course of chronic kidney disease, implying that Ang-2 may serve as a useful biomarker in these patients. However, the exact mechanisms of Ang-2 action in renal diseases remain unclear. Key Messages: We summarized the recent findings on Ang-2 in kidney diseases, including preclinical studies and clinical studies, aiming to provide a systematic understanding of the role of Ang-2 in these diseases.
Article
Ophthalmology
Emmi Kapiainen, Harri Elamaa, Ilkka Miinalainen, Valerio Izzi, Lauri Eklund
Summary: This study demonstrates the additive effect of Angpt4 in maintaining SC and activating Tie2, as well as the synergistic interaction between Angpt4 and Angpt2. The interplay between the angiopoietins is crucial for maintaining the integrity of the iridocorneal angle.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Haiyan Zhou, Tangting Chen, Yongjie Li, Jingcan You, Xin Deng, Ni Chen, Tian Li, Youkun Zheng, Rong Li, Mao Luo, Jianbo Wu, Liqun Wang
Summary: This study found that Tie-2 is modified by AGEs in diabetes, leading to the inhibition of Ang-1 signaling activation and angiogenesis. This finding provides a novel mechanism for Ang-1/Tie-2 signal dysfunction and angiogenesis failure in diabetic ischemic diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Paulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis, Paula Voabil, Marjolein de Bruijn, Simone Brokamp, Irene Reijers, Judith Versluis, Gahyathiri Nallan, Hannah Triscott, Elizabeth McDonald, Joshua Tay, Georgina Long, Christian U. Blank, Daniela S. Thommen, Michele W. L. Teng
Summary: Neoadjuvant immunotherapy with the combination of anti-CTLA4, anti-PD1, and IL-2 has shown improved efficacy in treating melanoma and breast cancer. The addition of IL-2 overcomes resistance to anti-CTLA4 and anti-PD1, leading to enhanced immune response. This combination therapy has potential for early-stage cancer patients.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Letter
Medicine, General & Internal
Benoit Rousseau, Michael B. Foote, Steven B. Maron, Bill H. Diplas, Steve Lu, Guillem Argiles, Andrea Cercek, Luis A. Diaz
Summary: The study demonstrated that improved overall survival in tumors with high mutational burden treated with immune checkpoint inhibitors was mainly associated with mutations in the POLE gene and defective DNA mismatch repair, rather than overall mutational burden.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Madeleine Benguigui, Avital Vorontsova, Michael Timaner, Sapir Levin, Jozafina Haj-Shomaly, Abhilash Deo, Rotem Menachem, Bar Manobla, Tim J. Cooper, Ziv Raviv, Yuval Shaked
Summary: It has been found that granulocytic-MDSCs (G-MDSCs) are enriched in anti-PD1 resistant tumors. Resistance to anti-PD1 monotherapy can be reversed by switching to a combined regimen of anti-Bv8 and anti-PD1 antibodies, which is associated with decreased G-MDSCs levels and enrichment of active cytotoxic T cells in tumors. Anti-Bv8 blockade is also effective in the hyperprogressive phenotype of anti-PD1-treated tumors. In vitro experiments show that anti-Bv8 antibodies directly inhibit MDSC-mediated immunosuppression. In conclusion, Bv8 blockade inhibits the immunosuppressive function of MDSCs, enhances the anti-tumor activity of cytotoxic T cells, and increases the sensitivity of anti-PD1-resistant tumors.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Tomasz Skowerski, Katarzyna Nabrdalik, Hanna Kwiendacz, Maciej Pajak, Katarzyna Mizia-Stec, Zbigniew Gasior, Janusz Gumprecht
Summary: This study found that serum concentration of Angiopoietin-2 (Ang-2) is elevated in non-ST elevation myocardial infarction (NSTEMI), regardless of the presence of type 2 diabetes mellitus (T2DM). The level of Ang-2 does not correspond with the degree of myocardial injury and hemodynamic status. The elevation of Ang-2 also occurs in T2DM patients without a history of coronary artery disease (CAD).
ARCHIVES OF MEDICAL SCIENCE
(2022)
Review
Immunology
Mohammad Hossein Kazemi, Alireza Najafi, Jafar Karami, Foad Ghazizadeh, Hassan Yousefi, Reza Falak, Elahe Safari
Summary: Recent advancements in cancer immunotherapy, particularly immune checkpoint (IC) blockers, have shown promising results in clinical settings. Immunometabolism plays a crucial role in regulating immune responses, and dual targeting of ICs and metabolic pathways may help restore immune cells' antitumor activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Neurosciences
Jeremie Canonica, Richard Foxton, Marina Garcia Garrido, Cheng-Mao Lin, Sabine Uhles, Sumathi Shanmugam, David A. Antonetti, Steven F. Abcouwer, Peter D. Westenskow
Summary: Clinical trials have shown that faricimab, a medication targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF-A), provides effective and long-lasting treatment for neovascular age-related macular degeneration and diabetic macular edema. However, the mechanism behind these results and the role of Ang-2 inhibition require further investigation.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2023)
Article
Immunology
Amelie Marguier, Caroline Laheurte, Benoit Lecoester, Marine Malfroy, Laura Boullerot, Adeline Renaudin, Evan Seffar, Abhishek Kumar, Charlee Nardin, Francois Aubin, Olivier Adotevi
Summary: This study investigates a novel subset of monocytic MDSCs called TIE-2(+) M-MDSCs in melanoma patients. These cells show a highly immunosuppressive phenotype and are associated with the pro-angiogenic factor ANGPT2. The study demonstrates that exposure to ANGPT2 increases the immune suppressive function of TIE-2(+) M-MDSCs and that active TIE-2 signaling is required for optimal suppressive activity. This suggests that the TIE-2(+) M-MDSC/ANGPT2 axis may play a role in immune escape in melanoma.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Daniel J. Gottlieb, David J. Lederer, John S. Kim, Russell P. Tracy, Su Gao, Susan Redline, Sanja Jelic
Summary: This study assessed the impact of positive airway pressure (PAP) therapy on alveolar epithelial and endothelial injury and extracellular matrix remodeling in patients with obstructive sleep apnea (OSA). The findings suggest a possible adverse impact of PAP therapy on vascular endothelium.
Article
Immunology
Cornelia A. M. van de Weg, Mateus Thomazella, Mariana P. Marmorato, Carolina A. Correia, Juliana Z. C. Dias, Alvino Maestri, Luiz G. F. A. B. E. Zanella, Natalia B. Cerqueira, Alvina C. Felix, Carlos H. Moreira, Renata Buccheri, Priscilla R. Costa, Esper G. Kallas
Summary: In a large yellow fever outbreak in Sao Paulo, Brazil in 2018, it was found that angiopoietin 2, a marker related to endothelial damage, is strongly associated with mortality. This suggests that angiopoietin 2 could serve as a predictive marker for fatal outcomes in yellow fever cases.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Gastroenterology & Hepatology
Gwang Hyeon Choi, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
Summary: Plasma levels of Ang-2 in HCC patients correlated with liver function, tumor stage, and tumor invasiveness, showing better performance in predicting OS and PFS compared to AFP, Ang-1, or VEGF.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Oncology
Russell Hughes, Bin-Zhi Qian, Charlotte Rowan, Munitta Muthana, Ioanna Keklikoglou, Oakley C. Olson, Simon Tazzyman, Sarah Danson, Christina Addison, Mark Clemons, Ana Maria Gonzalez-Angulo, Johanna A. Joyce, Michele De Palma, Jeffrey W. Pollard, Claire E. Lewis
Article
Oncology
Claire E. Lewis, Allison S. Harney, Jeffrey W. Pollard
Correction
Oncology
Claire E. Lewis, Allison S. Harney, Jeffrey W. Pollard
Article
Cell Biology
Ioanna Keklikoglou, Chiara Cianciaruso, Esra Guc, Mario Leonardo Squadrito, Laura M. Spring, Simon Tazzyman, Lore Lambein, Amanda Poissonnier, Gino B. Ferraro, Caroline Baer, Antonino Cassara, Alan Guichard, M. Luisa Iruela-Arispe, Claire E. Lewis, Lisa M. Coussens, Aditya Bardia, Rakesh K. Jain, Jeffrey W. Pollard, Michele De Palma
NATURE CELL BIOLOGY
(2019)
Article
Biochemistry & Molecular Biology
Nadine Rohwer, Sandra Jumpertz, Merve Erdem, Antje Egners, Klaudia T. Warzecha, Athanassios Fragoulis, Anja A. Kuehl, Rafael Kramann, Sabine Neuss, Ines Rudolph, Tobias Endermann, Christin Zasada, Ivayla Apostolova, Marco Gerling, Stefan Kempa, Russell Hughes, Claire E. Lewis, Winfried Brenner, Maciej B. Malinowski, Martin Stockmann, Lutz Schomburg, William Faller, Owen J. Sansom, Frank Tacke, Markus Morkel, Thorsten Cramer
Article
Oncology
Amy Kwan, Natalie Winder, Emer Atkinson, Haider Al-Janabi, Richard J. Allen, Russell Hughes, Mohammed Moamin, Rikah Louie, Dhanajay Evans, Matthew Hutchinson, Drew Capper, Katie Cox, Joshua Handley, Adam Wilshaw, Taewoo Kim, Simon J. Tazzyman, Sanjay Srivastava, Penelope Ottewell, Jayakumar Vadakekolathu, Graham Pockley, Claire E. Lewis, Janet E. Brown, Sarah J. Danson, Joe Conner, Munitta Muthana
Summary: This study demonstrates that oncolytic virus HSV1716 can activate the antitumor functions of immune cells and reprogram tumor-associated macrophages to a less immunosuppressive phenotype. HSV1716 administration led to marked tumor shrinkage in primary mammary tumors and a decrease in metastases, associated with increased recruitment/activation of cytotoxic T cells and a reduction in regulatory T cells.
MOLECULAR CANCER THERAPEUTICS
(2021)
Editorial Material
Oncology
Haider Al-Janabi, Claire E. Lewis
Summary: Androgen deprivation therapy (ADT) is a frontline treatment for early and metastatic prostate cancer, but tumor resistance to ADT can lead to major clinical consequences. Tumor-associated macrophages have been shown to drive tumor resistance to various anticancer therapies, and researchers have now identified a novel mechanism involving the transfer of cholesterol from macrophages to cancer cells during ADT, which activates androgen receptors and promotes tumor resistance.
Article
Nanoscience & Nanotechnology
Alessandra Iscaro, Christian Jones, Neil Forbes, Amina Mughal, Faith Nutter Howard, Haider Al Janabi, Secil Demiral, Yvonne Perrie, Magnus Essand, Aleksandra Weglarz, Luis J. Cruz, Claire E. Lewis, Munitta Muthana
Summary: This study demonstrates that encapsulating oncolytic adenovirus into CCL2-coated liposomes can effectively target tumors by recruiting circulating monocytes expressing CCR2. The nanomedicine approach significantly reduces tumor size and metastasis, providing a potential strategy for treating inaccessible tumors.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2022)
Meeting Abstract
Oncology
Anna Juncker-Jensen, Nicholas Stavrou, Mohammed Moamin, Mate Nagy, Richard Allen, Angela Cox, Claire Lewis
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Mohammed Ridha Moamin, Richard Allen, Steven Leslie Woods, Janet Elizabeth Brown, Harry Nunns, Anna Juncker-Jensen, Claire Elizabeth Lewis
Summary: This article investigates the distribution and interaction of immune cells in human TNBC and their response to NAC. The changes in certain cells may be associated with the risk of relapse. Additionally, the clustering of immune cells in perivascular areas may play a crucial role in the activation and function of T cells, and thus affect the efficacy of T cell-based immunotherapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Correction
Immunology
Antonio Lapenna, Michele De Palma, Claire E. Lewis
NATURE REVIEWS IMMUNOLOGY
(2021)
Meeting Abstract
Oncology
Mohammed Ridha Moamin, Richard J. Allen, Nicholas Stavrou, Mate Nagy, Anna Juncker-Jensen, Claire E. Lewis
Meeting Abstract
Oncology
Haider Al-Janabi, Xuan Pu, Munitta Muthana, Ning Wang, Mateus Crespo, Bora Gurel, Johann De Bono, Janet E. Brown, Claire E. Lewis
Meeting Abstract
Oncology
Xuan Pu, Haider AL-Janabi, Ning Wang, Munitta Muthana, Janet Brown, Claire Lewis
Review
Immunology
Antonio Lapenna, Michele De Palma, Claire E. Lewis
NATURE REVIEWS IMMUNOLOGY
(2018)
